Literature DB >> 19129252

Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.

Frank Park1, William E Sweeney, Guangfu Jia, Talha Akbulut, Benjamin Mueller, J Russell Falck, Saritha Birudaraju, Richard J Roman, Ellis D Avner.   

Abstract

20-Hydroxyeicosatetraenoic acid (20-HETE) has been implicated as a potential mediator in epithelial cell proliferation and cyst formation in polycystic kidney disease (PKD). In the present study, we studied the effects of chronic blockade of 20-HETE synthesis in an orthologous rodent model of autosomal recessive polycystic kidney disease (ARPKD), the PCK rat. RT-PCR analysis indicated that the expression of CYP4A1, CYP4A2, CYP4A3, and CYP4A8 mRNA was increased two- to fourfold in cystic PCK compared with noncystic Sprague-Dawley rat kidneys. Daily administration of a 20-HETE synthesis inhibitor, HET-0016 (10 mg x kg(-1) x day(-1) ip) for 4-7 wk significantly reduced kidney size by 24% from 4.95 +/- 0.19 g in vehicle-treated PCK rats to 3.76 +/- 0.15 g (n = 4). Collecting tubule morphometric cystic indices were reduced in HET-0016-treated PCK rats (2.1 +/- 0.2; n = 4) compared with vehicle-treated PCK rats (4.4 +/- 0.1; n = 4). The cellular mechanism by which 20-HETE may play a role in cyst formation has not been well characterized, but there was a significantly lower (P < 0.05) level of intracellular cAMP and decreased phosphorylation (activation) of ERK1/2 protein in PCK rat kidneys (n = 3) treated with HET-0016 . These studies indicate a potential role of 20-HETE in cyst formation in the orthologous rodent PCK model of ARPKD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129252      PMCID: PMC2660198          DOI: 10.1152/ajprenal.90705.2008

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  38 in total

1.  Role of CFTR in autosomal recessive polycystic kidney disease.

Authors:  Koichi Nakanishi; William E Sweeney; Katherine Macrae Dell; Calvin U Cotton; Ellis D Avner
Journal:  J Am Soc Nephrol       Date:  2001-04       Impact factor: 10.121

2.  Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

Authors:  Xiaofang Wang; Vincent Gattone; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

3.  Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor.

Authors:  W E Sweeney; Y Chen; K Nakanishi; P Frost; E D Avner
Journal:  Kidney Int       Date:  2000-01       Impact factor: 10.612

4.  The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.

Authors:  D J Lager; Q Qian; R J Bengal; M Ishibashi; V E Torres
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

5.  Inhibitors of cytochrome P450 4A suppress angiogenic responses.

Authors:  Ping Chen; Meng Guo; Dana Wygle; Paul A Edwards; John R Falck; Richard J Roman; A Guillermo Scicli
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

6.  Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors.

Authors:  M H Wang; E Brand-Schieber; B A Zand; X Nguyen; J R Falck; N Balu; M L Schwartzman
Journal:  J Pharmacol Exp Ther       Date:  1998-03       Impact factor: 4.030

7.  Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites.

Authors:  M M Muthalif; N A Karzoun; L Gaber; Z Khandekar; I F Benter; A E Saeed; J H Parmentier; A Estes; K U Malik
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

8.  cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells.

Authors:  Kazushige Hanaoka; William B Guggino
Journal:  J Am Soc Nephrol       Date:  2000-07       Impact factor: 10.121

9.  Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid.

Authors:  O Ito; K Omata; S Ito; K M Hoagland; R J Roman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-03       Impact factor: 3.619

10.  20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells.

Authors:  M M Muthalif; I F Benter; N Karzoun; S Fatima; J Harper; M R Uddin; K U Malik
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

View more
  12 in total

Review 1.  Conflicting roles of 20-HETE in hypertension and renal end organ damage.

Authors:  Chao Zhang; George W Booz; Qing Yu; Xiaochen He; Shaoxun Wang; Fan Fan
Journal:  Eur J Pharmacol       Date:  2018-06-07       Impact factor: 4.432

Review 2.  Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.

Authors:  Fan Fan; Richard J Roman
Journal:  J Am Soc Nephrol       Date:  2017-07-12       Impact factor: 10.121

3.  Loss of activator of G-protein signaling 3 impairs renal tubular regeneration following acute kidney injury in rodents.

Authors:  Kevin R Regner; Kandai Nozu; Stephen M Lanier; Joe B Blumer; Ellis D Avner; William E Sweeney; Frank Park
Journal:  FASEB J       Date:  2011-02-22       Impact factor: 5.191

4.  Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.

Authors:  Guangfu Jia; Michelle Kwon; Huan Ling Liang; Jordan Mortensen; Vani Nilakantan; William E Sweeney; Frank Park
Journal:  Pediatr Nephrol       Date:  2010-03-13       Impact factor: 3.714

Review 5.  Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.

Authors:  Fan Fan; Ying Ge; Wenshan Lv; Matthew R Elliott; Yoshikazu Muroya; Takashi Hirata; George W Booz; Richard J Roman
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

6.  20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and c-Src-dependent mechanism.

Authors:  Talha Akbulut; Kevin R Regner; Richard J Roman; Ellis D Avner; John R Falck; Frank Park
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-01

7.  Bioactive lipid mediators in polycystic kidney disease.

Authors:  Jelena Klawitter; Jost Klawitter; Kim McFann; Alexander T Pennington; Kaleab Z Abebe; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Berenice Gitomer; Uwe Christians; Robert W Schrier
Journal:  J Lipid Res       Date:  2013-12-16       Impact factor: 5.922

8.  Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy.

Authors:  Mahesha H Gangadhariah; James M Luther; Victor Garcia; Paisit Paueksakon; Ming-Zhi Zhang; Simon W Hayward; Harold D Love; John R Falck; Vijaya L Manthati; John D Imig; Michal L Schwartzman; Roy Zent; Jorge H Capdevila; Ambra Pozzi
Journal:  J Am Soc Nephrol       Date:  2014-07-28       Impact factor: 10.121

9.  Cyclooxygenase-2 dependent metabolism of 20-HETE increases adiposity and adipocyte enlargement in mesenchymal stem cell-derived adipocytes.

Authors:  Dong Hyun Kim; Nitin Puri; Komal Sodhi; John R Falck; Nader G Abraham; Joseph Shapiro; Michal L Schwartzman
Journal:  J Lipid Res       Date:  2013-01-04       Impact factor: 5.922

10.  Caroli's Disease: Current Knowledge of Its Biliary Pathogenesis Obtained from an Orthologous Rat Model.

Authors:  Yasunori Sato; Xiang Shan Ren; Yasuni Nakanuma
Journal:  Int J Hepatol       Date:  2011-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.